Omeprazole Olikla

Omeprazole, the active ingredient in Omeprazole Olikla, is a proton pump inhibitor presented as an oral tablet for systemic use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders such as reflux disease, ulcers and erosive esophagitis, and is often prescribed by gastroenterologists to improve symptom control in adult patients.

GNH USA supplies Omeprazole Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with reliable logistics and quality assurance.

Omeprazole is a proton pump inhibitor that decreases gastric acid secretion, making it useful for several acid‑related conditions. - Gastroesophageal reflux disease (GERD): provides symptom relief and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic therapy by maintaining a less acidic gastric environment. - Erosive esophagitis: facilitates mucosal repair and alleviates pain.

Omeprazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild pain or pressure in the head. - Diarrhea: loose, watery stools. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing, rash. - Clostridioides difficile infection: persistent diarrhea with abdominal pain. - Low blood magnesium (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: signs of hepatic stress that may require monitoring.

When prescribing Omeprazole, clinicians should consider several safety precautions to minimize risks. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor magnesium levels: prolonged therapy can lead to hypomagnesemia. - Use cautiously in hepatic disease: reduced metabolism may increase exposure. - Review concomitant medications: potential for drug‑drug interactions. - Counsel patients on rebound acid hypersecretion: symptoms may recur after abrupt discontinuation. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Omeprazole can affect the plasma concentrations of several co‑administered drugs, requiring attention to interaction potential.

Major Interactions (Avoid): - Ketoconazole and other azole antifungals: reduced absorption due to increased gastric pH. - Atazanavir (and other protease inhibitors): markedly decreased antiviral efficacy. - Clarithromycin: increased risk of elevated omeprazole levels and cardiac effects.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced antiplatelet activity. - Warfarin: possible alteration of anticoagulant effect. - Methotrexate: increased serum concentrations, especially with high‑dose therapy.